Treatment in resectable, locally advanced NSCLC: which is the best approach?

References

• Mountain C. Revisions in the international system for staging lung cancer. Chest111, 1710–1717 (1997).
   PubMed Web of Science ®Google Scholar
• Berghmans T, Paesmans M, Meert AP et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer49, 13–23 (2005).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J.311, 899–909 (1995).
   PubMed Web of Science ®Google Scholar
• Keller S, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA NSCLC (ECOG) N. Engl. J. Med.343, 1217–1222 (2000).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J. Natl Cancer Inst.95, 1453–1461 (2003).
   PubMed Web of Science ®Google Scholar
• Arriagada R, Bergmann B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med.350, 351–360 (2004).
   PubMed Web of Science ®Google Scholar
• Hotta K, Matsuo K, Ueoka H et al. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J. Clin. Oncol.22, 3860–3867 (2004).
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs, observation in resected non-small cell lung cancer (NCIC). N. Engl. J. Med.352, 2589–2597 (2005).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected IB-IIIA non-small cell lung cancer. (Adjuvant Navelbine International Trialist Association [ANITA]: a randomized controlled trial.) Lancet Oncol.7, 719–727 (2006).
   PubMed Web of Science ®Google Scholar
• Strauss GM, Herndon JE, Maddaus MA et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J. Clin. Oncol.24, 365S A7007 (2006).
   Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol.26, 3553–3559 (2008)
   Google Scholar
• Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl Cancer Inst.86, 673–680 (1994).
   PubMed Web of Science ®Google Scholar
• Pass HI, Pogrebniak HW, Steinberg SM. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thorac. Surg.53, 992–998 (1992).
   PubMed Web of Science ®Google Scholar
• Rosell R, Gomez-Codina J, Camps C. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med.330, 153–158 (1994).
   PubMed Web of Science ®Google Scholar
• Mattson KV, Abratt RP, ten Velde G and Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomized Phase III study. Ann. Oncol.14, 116–122 (2003).
   PubMed Web of Science ®Google Scholar
• Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except t1n0), II, and IIIA non–small-cell lung cancer. J. Clin. Oncol.20, 247–253 (2002).
   PubMed Web of Science ®Google Scholar
• Pisters K, Vallieres E, Bunn P et al. S9900: a Phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin chemotherapy in early stage non-small cell lung cancer, preliminary results. J. Clin. Oncol.23(16 Suppl.), S7012. Presented at: 42nd ASCO Annual Meeting. Orlando, FL, USA, 13–17 May 2005.
   Google Scholar
• Gilligan D, Nicolson M, Smith I et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet369, 1929–1937 (2007).
   PubMed Web of Science ®Google Scholar
• Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J. Thorac. Oncol.1, 611–621 (2006).
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer10(Suppl. 1), S239–S244 (1994).
   Web of Science ®Google Scholar
• Rolle A, Gunzer R, Pachmann U et al. Increase number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC is a predictor for relapse: a preliminary report. World J. Surg. Oncol.3, 18–26 (2005).
   PubMedGoogle Scholar
• Eberhardt WE. Randomized multicenter german trial of surgery plus radiotherapy versus tri-modality treatment of operable stage IIIA NSCLC – long-term follow-up results. J. Thoracic Oncol.2(4 Suppl.), S311. Presented at: 12th World Conference of Lung Cancer. Seoul, Korea, 2–6 September 2007.
   Google Scholar
• Depierre A, Milleron B, Quoix E et al. Phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy (CT) with two different CT regimens in resectable stage I–II non-small cell lung cancer (NSCLC): the IFCT 0002 protocol. J. Thoracic Oncol.2, S4, S366. Presented at: 12th World Conference of Lung Cancer. Seoul, Korea, 2–6 September 2007.
   Google Scholar
• Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIA (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann.Thor. Surg.55, 1365–1373 (1993).
   PubMed Web of Science ®Google Scholar
• Pisters KM, Kris MG, Gralla RJ et al. Pathologic complete response in advanced non-small cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J. Clin. Oncol.11, 1757–1762 (1993).
   PubMed Web of Science ®Google Scholar
• Burkes RL, Shepherd FA, Blackstein ME et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage IIIA (T1–3, N2) unresectable non-small cell lung cancer: final results of the Toronto Phase II trial. Lung Cancer47, 103–109 (2005).
   PubMed Web of Science ®Google Scholar
• Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-lung cancer : mature results of southwest oncology group Phase II study 8805. J. Clin. Oncol.13, 1880–1892 (1995).
   PubMed Web of Science ®Google Scholar
• Strauss G. Author update of neoadjuvant chemotherapy and radiotherapy followed by surgery. Classic Pap. Curr.Comments2, 150–159 (1997).
   Google Scholar
• Sugarbaker DJ, Herndon J, Kohman LJ et al. Results of cancer and leukaemia group B protocol 8935. A multi-institutional Phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg.109, 473–483 (1995).
   PubMed Web of Science ®Google Scholar
• Faber LP, Kittle CF, Warren WH et al. Preoperative chemotherapy and irradiation for stage III non-small-cell lung cancer. Ann. Thorac. Surg.47, 669–675 (1989).
   PubMed Web of Science ®Google Scholar
• Betticher DC, Hsu Schmitz SF, Tötsch M et al. Mediastinal lymph node clearance after docetaxel–cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIa PN2 non-small-cell lung cancer: a multicenter Phase II trial. J. Clin. Oncol.21, 1752–1759 (2003).
   PubMed Web of Science ®Google Scholar
• Betticher DC, Hsu Schmitz SF, Tötsch M et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5 year follow-up of a Phase II study. Br. J. Cancer94, 1099–1106 (2006).
   PubMed Web of Science ®Google Scholar
• van Meerbeck JP, Kramer GW, van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer (EORTC 08941). J. Natl Cancer Inst.21(99), 442–450 (2007).
   Google Scholar
• Albain KS, Swann RS, Rusch VR et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J. Clin. Oncol.23(16Suppl.), 7014 (2005).
   Google Scholar